Payment overview · 2025
General Payments
$200.79
10 reported records · 7 companies
Healthcare provider profile · identity verified
Celeste T. Jackson, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · GREENVILLE, NC · NPI 1043447410
Verified facts
What the public records show
CMS Open Payments records show Celeste T. Jackson, M.D. received $200.79 in general payments during 2025 across 10 reported records.
Abbott Laboratories accounted for 35.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $71.27 | 35.5% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $30.21 | 15.1% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $29.30 | 14.6% | 1 | 2025 |
| The Binding Site Inc. | Unresolved — no canonical attribution shown | $19.36 | 9.6% | 1 | 2025 |
| Tactile Systems Technology Inc | Unresolved — no canonical attribution shown | $19.10 | 9.5% | 1 | 2025 |
| Phadia US Inc. | Unresolved — no canonical attribution shown | $16.24 | 8.1% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$15.31 | 7.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $200.79 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $71.27 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $30.21 | 2 | 2025 |
Source payment records
|
|||||
| WaveWriter Alpha Prime 16 Normalized: wavewriter alpha prime 16 |
Device | Boston Scientific Corporation | $29.30 | 1 | 2025 |
Source payment records
|
|||||
| Freelite Normalized: freelite |
Device | The Binding Site Inc. | $19.36 | 1 | 2025 |
Source payment records
|
|||||
| Flexitouch Plus Normalized: flexitouch plus |
Device | Tactile Systems Technology Inc | $19.10 | 1 | 2025 |
Source payment records
|
|||||
| Nimbl Normalized: nimbl |
Device | Tactile Systems Technology Inc | $19.10 | 1 | 2025 |
Source payment records
|
|||||
| ImmunoCAP Normalized: immunocap |
Device | Phadia US Inc. | $16.24 | 1 | 2025 |
Source payment records
|
|||||
| INTELLIS ADAPTIVESTIM Normalized: intellis adaptivestim |
Device | Medtronic, Inc. | $15.31 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 382 | 116 |
| Amlodipine Besylate | Amlodipine Besylate | 278 | 76 |
| Gabapentin | Gabapentin | 247 | 58 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 214 | 68 |
| Lisinopril | Lisinopril | 208 | 62 |
| Losartan Potassium | Losartan Potassium | 184 | 49 |
| Hydrochlorothiazide | Hydrochlorothiazide | 173 | 50 |
| Furosemide | Furosemide | 167 | 50 |
| Omeprazole | Omeprazole | 161 | 40 |
| Metoprolol Succinate | Metoprolol Succinate | 145 | 42 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 138 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 137 | 58 |
| Levothyroxine Sodium | Levothyroxine Sodium | 134 | 35 |
| Potassium Chloride | Potassium Chloride | 125 | 38 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 123 | 41 |
| Tizanidine Hcl | Tizanidine Hcl | 122 | 33 |
| Simvastatin | Simvastatin | 109 | 30 |
| Metoprolol Tartrate | Metoprolol Tartrate | 104 | 27 |
| Trazodone Hcl | Trazodone Hcl | 102 | 26 |
| Metformin Hcl | Metformin Hcl | 96 | 32 |
| Metformin Hcl Er | Metformin Hcl | 95 | 31 |
| Pregabalin | Pregabalin | 90 | 15 |
| Alendronate Sodium | Alendronate Sodium | 84 | 22 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 82 | 30 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 82 | 18 |
| Famotidine | Famotidine | 77 | 22 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 77 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 75 | 18 |
| Tramadol Hcl | Tramadol Hcl | 75 | 17 |
| Ozempic | Semaglutide | 72 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 71 | 23 |
| Jardiance | Empagliflozin | 71 | 22 |
| Eliquis | Apixaban | 69 | 16 |
| Farxiga | Dapagliflozin Propanediol | 69 | 19 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 68 | 24 |
| Ezetimibe | Ezetimibe | 66 | 24 |
| Meclizine Hcl | Meclizine Hcl | 62 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 60 | 16 |
| Promethazine Hcl | Promethazine Hcl | 60 | 13 |
| Buspirone Hcl | Buspirone Hcl | 59 | 14 |
| Allopurinol | Allopurinol | 56 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 55 | 14 |
| Oxycodone Hcl | Oxycodone Hcl | 52 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 52 | 20 |
| Tamsulosin Hcl | Tamsulosin Hcl | 52 | 18 |
| Trulicity | Dulaglutide | 52 | suppressed |
| Carvedilol | Carvedilol | 49 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 48 | 16 |
| Tradjenta | Linagliptin | 48 | suppressed |
| Fluconazole | Fluconazole | 46 | 26 |
| Spironolactone | Spironolactone | 45 | 13 |
| Sertraline Hcl | Sertraline Hcl | 43 | 11 |
| Xarelto | Rivaroxaban | 43 | suppressed |
| Baclofen | Baclofen | 41 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 40 | 11 |
| Montelukast Sodium | Montelukast Sodium | 40 | 14 |
| Morphine Sulfate Er | Morphine Sulfate | 40 | suppressed |
| Azithromycin | Azithromycin | 38 | 33 |
| Donepezil Hcl | Donepezil Hcl | 35 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 35 | suppressed |
| Lovastatin | Lovastatin | 33 | suppressed |
| Atenolol | Atenolol | 32 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 31 | suppressed |
| Ondansetron Odt | Ondansetron | 31 | 16 |
| Clonazepam | Clonazepam | 30 | suppressed |
| Novolog Flexpen | Insulin Aspart | 30 | suppressed |
| Xtampza Er | Oxycodone Myristate | 30 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 28 | 26 |
| Clopidogrel | Clopidogrel Bisulfate | 28 | suppressed |
| Prednisone | Prednisone | 28 | 24 |
| Benazepril Hcl | Benazepril Hcl | 27 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 27 | 15 |
| Eszopiclone | Eszopiclone | 27 | suppressed |
| Naproxen | Naproxen | 27 | 11 |
| Nifedipine Er | Nifedipine | 27 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 27 | suppressed |
| Chlorthalidone | Chlorthalidone | 26 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 26 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 25 | 20 |
| Estradiol | Estradiol | 25 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 25 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 24 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 24 | suppressed |
| Ibuprofen | Ibuprofen | 24 | suppressed |
| Lorazepam | Lorazepam | 24 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 24 | suppressed |
| Synthroid | Levothyroxine Sodium | 24 | suppressed |
| Valsartan | Valsartan | 24 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 24 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 23 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 23 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 23 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 22 | suppressed |
| Colchicine | Colchicine | 22 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 22 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Glimepiride | Glimepiride | 21 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 21 | 12 |
| Celecoxib | Celecoxib | 20 | suppressed |
| Klor-Con M20 | Potassium Chloride | 20 | suppressed |
| Linzess | Linaclotide | 20 | 13 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | 18 |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Amoxicillin | Amoxicillin | 19 | 19 |
| Enalapril Maleate | Enalapril Maleate | 19 | suppressed |
| Glipizide Er | Glipizide | 19 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 19 | suppressed |
| Mupirocin | Mupirocin | 19 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 19 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 18 | suppressed |
| Fenofibrate | Fenofibrate | 18 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 18 | suppressed |
| Alprazolam | Alprazolam | 17 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Hydrocortisone | Hydrocortisone | 17 | 11 |
| Lactulose | Lactulose | 17 | suppressed |
| Mirtazapine | Mirtazapine | 17 | suppressed |
| Restasis | Cyclosporine | 17 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 17 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 16 | suppressed |
| Carisoprodol | Carisoprodol | 16 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 15 | suppressed |
| Memantine Hcl | Memantine Hcl | 15 | suppressed |
| Oxycontin | Oxycodone Hcl | 15 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 14 | suppressed |
| Invokana | Canagliflozin | 14 | suppressed |
| Januvia | Sitagliptin Phosphate | 14 | suppressed |
| Mounjaro | Tirzepatide | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 13 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 13 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Rybelsus | Semaglutide | 12 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 12 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Belsomra | Suvorexant | 11 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $200.79 · 10 records | Abbott Laboratories | Cologuard Collection Kit, FREESTYLE LIBRE 3, Flexitouch Plus, Freelite, INTELLIS ADAPTIVESTIM, ImmunoCAP, Nimbl, WaveWriter Alpha Prime 16 | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error